Association of Serum Myostatin with Body Weight, Visceral Fat Volume, and High Sensitivity C-Reactive Protein But Not With Muscle Mass and Physical Fitness in Premenopausal Women

Abstract

Background The myokine myostatin regulates muscle mass and has been linked to insulin resistance and metabolic syndrome. However, data on its role in humans is still limited. We, therefore, investigated the associations of serum myostatin with muscle mass, physical fitness, and components of the metabolic syndrome in a cohort of premenopausal women.

Methods We undertook a cross-sectional analysis of 233 women from the monocenter study PPSDiab, conducted in Munich, Germany. Participants had recently completed a pregnancy with or without gestational diabetes. Our analysis included medical history, anthropometrics, oral glucose tolerance testing, laboratory chemistry, cardiopulmonary exercise testing, and magnetic resonance imaging (n=142) of visceral fat volume, left quadriceps muscle mass, and muscle fat content. Serum myostatin was quantified by a competitive enzyme-linked immunosorbent assay.

Results We observed positive correlations of serum myostatin with body mass index (ρ=0.235; p=0.0003), body fat percentage (ρ=0.166; p=0.011), waist circumference (ρ=0.206; p=0.002), intraabdominal fat volume (ρ=0.182; p=0.030) and high-sensitivity C-reactive protein (ρ=0.175; p=0.008). These correlations were reproduced in linear regression analyses with adjustment for age and time after delivery. We saw no correlations with muscle mass, physical fitness, insulin sensitivity, triglycerides, HDL cholesterol, and blood pressure.

Conclusions Our observation of elevated serum myostatin in women with a higher body fat percentage, visceral obesity, and elevated c-reactive protein suggests that this myokine contributes to the altered muscle-adipose tissue crosstalk in metabolic syndrome. Elevated myostatin may advance this pathophysiologic process and could also impair the efficacy of exercise interventions. Further mechanistic studies, therefore, seem warranted.

Key words

diabetes risk - myokines - adipose tissue - ergospirometry - MRI measurement of muscle mass

Publication History

Received: 29 January 2021
Received: 15 April 2021

Article published online:
18 August 2021

• References

• 1 McPherron AC, Lawler AM, Lee S-J. Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member. Nature 1997; 387: 83-90 doi:10.1038/387083a0
• 2 McPherron AC. Metabolic functions of myostatin and GDF11. Immunol Endocr Metab Agents Med Chem 2010; 10: 217-231 doi:10.2174/187152210793663810
• 3 Allen DL, Cleary AS, Speaker KJ. et al. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab 2008; 294: E918-E927 doi:10.1152/ajpendo.00798.2007
• 4 Lin J, Arnold HB, Della-Fera MA. et al. Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem Biophys Res Commun 2002; 291: 701-706 doi:10.1006/bbrc.2002.6500
• 5 Schuelke M, Wagner KR, Stolz LE. et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004; 350: 2682-2688 doi:10.1056/NEJMoa040933
• 6 Delanaye P, Bataille S, Quinonez K. et al. Myostatin and insulin-like growth factor 1 are biomarkers of muscle strength, muscle mass, and mortality in patients on hemodialysis. J Ren Nutr 2019; 29: 511-520 doi:10.1053/j.jrn.2018.11.010
• 7 Esposito P, Battaglia Y, La Porta E. et al. Significance of serum myostatin in hemodialysis patients. BMC Nephrol 2019; 20: 462 doi:10.1186/s12882-019-1647-9
• 8 Carvalho LP, Basso-Vanelli RP, Di Thommazo-Luporini L. et al. Myostatin and adipokines: The role of the metabolically unhealthy obese phenotype in muscle function and aerobic capacity in young adults. Cytokine 2018; 107: 118-124 doi:10.1016/j.cyto.2017.12.008
• 9 Amor M, Itariu BK, Moreno-Viedma V. et al. Serum myostatin is upregulated in obesity and correlates with insulin resistance in humans. Exp Clin Endocrinol Diabetes 2018;
• 10 Hittel DS, Axelson M, Sarna N. et al. Myostatin decreases with aerobic exercise and associates with insulin resistance. Med Sci Sports Exerc 2010; 42: 2023-2029 doi:10.1249/MSS.0b013e3181e0b9a8
• 11 Brandt C, Nielsen AR, Fischer CP. et al. Plasma and muscle myostatin in relation to type 2 diabetes. PloS one 2012; 7: e37236 doi:10.1371/journal.pone.0037236
• 12 Feig DS, Zinman B, Wang X. et al. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. Can Med Assoc J 2008; 179: 229-234 doi:10.1503/cmaj.080012
• 13 Gar C, Rottenkolber M, Grallert H. et al. Physical fitness and plasma leptin in women with recent gestational diabetes. PLoS One 2017; 12: e0179128 doi:10.1371/journal.pone.0179128
• 14 Roth SM, Walsh S. Myostatin: a therapeutic target for skeletal muscle wasting. Curr Opin Clin Nutr Metab Care 2004; 7: 259-263 doi:10.1097/00075197-200405000-00004
• 15 Chen MJ, Han DS, Yang JH. et al. Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome. Hum Reprod 2012; 27: 2476-2483 doi:10.1093/humrep/des209
• 16 Hittel DS, Berggren JR, Shearer J. et al. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009; 58: 30-38 doi:10.2337/db08-0943
• 17 Rottenkolber M, Ferrari U, Holland L. et al. The diabetes risk phenotype of young women with recent gestational diabetes. J Clin Endocrinol Metab 2015; 100: E910-E918 doi:10.1210/jc.2014-3898
• 18 Metzger BE, Gabbe SG, Persson B. et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33: 676-682 doi: 10.2337/dc09-1848
• 19 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470
• 20 Wintgens KF, Dschietzig T, Stoeva S. et al. Plasma myostatin measured by a competitive ELISA using a highly specific antiserum. Clin Chim Acta 2012; 413: 1288-1294 doi:10.1016/j.cca.2012.04.023
• 21 Pons C, Borotikar B, Garetier M. et al. Quantifying skeletal muscle volume and shape in humans using MRI: A systematic review of validity and reliability. PloS one 2018; 13: e0207847 doi:10.1371/journal.pone.0207847
• 22 Hogrel JY, Barnouin Y, Azzabou N. et al. NMR imaging estimates of muscle volume and intramuscular fat infiltration in the thigh: Variations with muscle, gender, and age. Age (Dordr) 2015; 37: 9798 doi:10.1007/s11357-015-9798-5
• 23 Mersmann F, Bohm S, Schroll A. et al. Muscle shape consistency and muscle volume prediction of thigh muscles. Scand J Med Sci Sports 2015; 25: e208-e213 doi: 10.1111/sms.12285
• 24 Torriani M, Thomas BJ, Halpern EF. et al. Intramyocellular lipid quantification: repeatability with 1H MR spectroscopy. Radiology 2005; 236: 609-614 doi:10.1148/radiol.2362041661
• 25 Dong J, Dong Y, Dong Y. et al. Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues. Int J Obes (Lond) 2016; 40: 434-442 doi:10.1038/ijo.2015.200
• 26 Nesto RW. Obesity: a major component of the metabolic syndrome. Tex Heart Inst J 2005; 32: 387-389
• 27 Rodríguez A, Becerril S, Ezquerro S. et al. Crosstalk between adipokines and myokines in fat browning. Acta Physiol (Oxf) 2017; 219: 362-381 doi: 10.1111/apha.12686
• 28 Assyov YS, Velikova TV, Kamenov ZA. Myostatin and carbohydrate disturbances. Endocr Res 2017; 42: 102-109 doi:10.1080/07435800.2016.1198802
• 29 Matsakas A, Foster K, Otto A. et al. Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice. Neuromuscul Disord 2009; 19: 489-499 doi:10.1016/j.nmd.2009.06.367
• 30 Zhu X, Hadhazy M, Wehling M. et al. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett 2000; 474: 71-75 doi:10.1016/s0014-5793(00)01570-2
• 31 Reisz-Porszasz S, Bhasin S, Artaza JN. et al. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 2003; 285: E876-E888 doi:10.1152/ajpendo.00107.2003
• 32 Lakshman KM, Bhasin S, Corcoran C. et al. Measurement of myostatin concentrations in human serum: Circulating concentrations in young and older men and effects of testosterone administration. Mol Cell Endocrinol 2009; 302: 26-32 doi:10.1016/j.mce.2008.12.019
• 33 Zimmers TA, Davies MV, Koniaris LG. et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002; 296: 1486-1488 doi:10.1126/science.1069525